France Biologics Market Size & Outlook, 2024-2030
France biologics market, 2018-2030 (US$M)
Related Markets
France biologics market highlights
- The France biologics market generated a revenue of USD 22.9 million in 2024 and is expected to reach USD 40.1 million by 2030.
- The France market is expected to grow at a CAGR of 9.8% from 2025 to 2030.
- In terms of segment, microbial was the largest revenue generating biologics source in 2024.
- Others Biologics Source is the most lucrative biologics source segment registering the fastest growth during the forecast period.
Biologics market data book summary
| Market revenue in 2024 | USD 22.9 million |
| Market revenue in 2030 | USD 40.1 million |
| Growth rate | 9.8% (CAGR from 2024 to 2030) |
| Largest segment | Microbial |
| Fastest growing segment | Others Biologics Source |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Microbial, Mammalian, Others Biologics Source |
| Key market players worldwide | Samsung BioLogics, Amgen Inc, Novo Nordisk A/S ADR, AbbVie Inc, Sanofi SA, Johnson & Johnson, Celltrion Healthcare, Bristol-Myers Squibb Co, Eli Lilly and Co, Roche Holding AG ADR |
Other key industry trends
- In terms of revenue, France accounted for 4.0% of the global biologics market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany biologics market is projected to lead the regional market in terms of revenue in 2030.
- Spain is the fastest growing regional market in Europe and is projected to reach USD 26.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Biologics Market Scope
Biologics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
France biologics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biologics market will help companies and investors design strategic landscapes.
Microbial was the largest segment with a revenue share of 58.08% in 2024. Horizon Databook has segmented the France biologics market based on microbial, mammalian, others biologics source covering the revenue growth of each sub-segment from 2018 to 2030.
- France Biologics Product Outlook (Revenue, USD Million, 2018-2030)
- Monoclonal antibodies (MABs)
- Vaccines
- Recombinant Proteins
- Antisense & RNAi Therapeutics
- Others
- France Biologics Disease Category Outlook (Revenue, USD Million, 2018-2030)
- Oncology
- Immunological Disorders
- Infectious diseases
- Ophthalmology
- Pre-filled syringes
- Other Delivery System
- Cardiovascular Disorders
- Hematological Disorders
- Others
- France Biologics Dosage Form Outlook (Revenue, USD Million, 2018-2030)
- Injectable Dosage Forms
- Prefilled Syringes
- Vials
- Others
- Others
- Injectable Dosage Forms
Reasons to subscribe to France biologics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of France biologics market databook
-
Our clientele includes a mix of biologics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the France biologics market , including forecasts for subscribers. This country databook contains high-level insights into France biologics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
France Biologics Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
